NCT00000775View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine

Trial Locations (2)

14642

Univ of Rochester Med Ctr, Rochester

63104

St Louis Univ School of Medicine, St Louis

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH